Site icon The Sways

Emcure Pharmaceuticals Limited IPO of Rs 1,952.03 crores (Emcure Pharma IPO) Detail

The issue is a combination of fresh issue of 0.79 crore shares Emcure Pharma IPO is a book built issue of Rs 1,952.03 crores.

aggregating to Rs 800.00 crores and offer for sale of 1.14 crore shares aggregating to Rs 1,152.03 crores.

IPO opens for subscription on July 3, 2024 and closes on July 5, 2024. The allotment for the Emcure Pharma IPO is expected to be finalized on Monday, July 8, 2024. Emcure Pharma IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, July 10, 2024.

 

Emcure Pharma IPO price band is set at ₹960 to ₹1008 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is ₹14,112. The minimum lot size investment for sNII is 15 lots (210 shares), amounting to ₹211,680, and for bNII, it is 71 lots (994 shares), amounting to ₹1,001,952.

Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited and Jefferies India Private Limited are the book running lead managers of the Emcure Pharma IPO, while Link Intime India Private Ltd is the registrar for the issue.

Refer to Emcure Pharma IPO RHP for detailed information.

About Emcure Pharmaceuticals Limited

Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.

The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.

In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company’s total revenue, respectively. The company’s Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.

As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.

Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.

As of September 30, 2023, the company’s marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.

Emcure Pharma IPO Details

PO DateJuly 3, 2024 to July 5, 2024
Listing Date[.]
Face Value₹10 per share
Price Band₹960 to ₹1008 per share
Lot Size14 Shares
Total Issue Size19,365,346 shares (aggregating up to ₹1,952.03 Cr)
Fresh Issue7,936,507 shares (aggregating up to ₹800.00 Cr)
Employee DiscountRs 90 per share
Issue TypeBook Built Issue IPO
Listing AtBSE, NSE
Share holding pre issue180,852,116
Share holding post issue188,788,623

Emcure Pharma IPO Reservation

Investor CategoryShares Offered
QIB Shares OfferedNot more than 50% of the Net Issue
Retail Shares OfferedNot less than 35% of the Net Issue
NII (HNI) Shares OfferedNot more than 15% of the Net Issue

Emcure Pharma IPO Timeline (Tentative Schedule)

Emcure Pharma IPO opens on July 3, 2024, and closes on July 5, 2024
IPO Open DateWednesday, July 3, 2024
IPO Close DateFriday, July 5, 2024
Basis of AllotmentMonday, July 8, 2024
Initiation of RefundsTuesday, July 9, 2024
Credit of Shares to DematTuesday, July 9, 2024
Listing DateWednesday, July 10, 2024
Cut-off time for UPI mandate confirmation5 PM on July 5, 2024

Emcure Pharma IPO Lot Size

Investors can bid for a minimum of 14 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
ApplicationLotsSharesAmount
Retail (Min)114₹14,112
Retail (Max)14196₹197,568
S-HNI (Min)15210₹211,680
S-HNI (Max)70980₹987,840
B-HNI (Min)71994₹1,001,952

Emcure Pharma IPO Promoter Holding

Satish Mehta and Sunil Mehta are the company promoters.
Share Holding Pre Issue98.90%
Share Holding Post Issue

Emcure Pharmaceuticals Limited Financial Information (Restated Consolidated)

Emcure Pharmaceuticals Limited's revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets7,806.166,672.536,063.47
Revenue6,715.246,031.725,918.86
Profit After Tax527.58561.85702.56
Net Worth2,952.282,501.131,987.55
Reserves and Surplus2,722.402,293.771,791.03
Total Borrowing2,091.942,202.422,102.19

Key Performance Indicator

The market capitalization of Emcure Pharma IPO is Rs 19029.89 Cr.
KPIValues
ROE16.90%
ROCE19.37%
Debt/Equity0.67
RoNW16.87%
P/BV6.18
Pre IPOPost IPO
EPS (Rs)29.1727.95
P/E (x)34.5536.07

Note:

Exit mobile version